The AKT/NF-κB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration

Biochemical Pharmacology

Volumn 83, Issue 12, 2012, Pages 1634-1642

  Benelli, Roberto ^a   Ven, Roberta ^a   Ciarlo, Monica ^a   Carlone, Sebastiano ^a   Barbieri, Ottavia ^a   Ferrari, Nicoletta ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

ALL; Chemoprevention; Chemoresistance; Migration; Xanthohumol

Indexed keywords

ANTILEUKEMIC AGENT; DOXORUBICIN; FOCAL ADHESION KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; XANTHOHUMOL;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INVASION; CELL CLONE; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EXPOSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LIFESPAN; LONG TERM EXPOSURE; METASTASIS; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; LEUKEMIC INFILTRATION; MICE; NF-KAPPA B; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPIOPHENONES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84860146666     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.03.006     Document Type: Article

References (42)

1. C.H. Pui, L.L. Robison, and A.T. Look Acute lymphoblastic leukemia Lancet 371 2008 1030 1043
2. C.H. Pui, and W.E. Evans Treatment of acute lymphoblastic leukemia The New England Journal of Medicine 354 2006 166 178
3. C.H. Pui, M.V. Relling, J.T. Sandlund, J.R. Downing, D. Campana, and W.E. Evans Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia Annals of Hematology 83 Suppl 1 2004 S124 S126
4. G. Wei, D. Twomey, J. Lamb, K. Schlis, J. Agarwal, and R.W. Stam Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance Cancer Cell 10 2006 331 342
5. T. Palomero, M. Dominguez, and A.A. Ferrando The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia Cell Cycle 7 2008 965 970 (Georgetown, Tex)
6. A. Gutierrez, and A.T. Look NOTCH and PI3K-AKT pathways intertwined Cancer Cell 12 2007 411 413
7. A. Silva, J.A. Yunes, B.A. Cardoso, L.R. Martins, P.Y. Jotta, and M. Abecasis PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability Journal of Clinical Investigation 118 2008 3762 3774
8. M.G. Kharas, and D.A. Fruman ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors Cancer Research 65 2005 2047 2053
9. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, and F. Chang Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochimica et Biophysica Acta 1773 2007 1263 1284
10. B.B. Aggarwal, H. Ichikawa, P. Garodia, P. Weerasinghe, G. Sethi, and I.D. Bhatt From traditional ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer Expert Opinion on Therapeutic Targets 10 2006 87 118
11. C. Gerhauser, A. Alt, E. Heiss, A. Gamal-Eldeen, K. Klimo, and J. Knauft Cancer chemopreventive activity of xanthohumol, a natural product derived from hop Molecular Cancer Therapeutics 1 2002 959 969
12. S. Lust, B. Vanhoecke, A. Janssens, J. Philippe, M. Bracke, and F. Offner Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism Molecular Nutrition & Food Research 49 2005 844 850
13. B. Vanhoecke, L. Derycke, V. Van Marck, H. Depypere, D. De Keukeleire, and M. Bracke Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer International Journal of Cancer 117 2005 889 895
14. L. Pan, H. Becker, and C. Gerhauser Xanthohumol induces apoptosis in cultured 40-16 human colon cancer cells by activation of the death receptor- and mitochondrial pathway Molecular Nutrition & Food Research 49 2005 837 843
15. L. Delmulle, T. Vanden Berghe, D.D. Keukeleire, and P. Vandenabeele Treatment of PC-3 and DU145 prostate cancer cells by prenylflavonoids from hop (Humulus lupulus L.) induces a caspase-independent form of cell death Phytotherapy Research 22 2008 197 203
16. A. Albini, R. Dell'Eva, R. Vene, N. Ferrari, D.R. Buhler, and D.M. Noonan Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets FASEB Journal 20 2006 527 529
17. E.C. Colgate, C.L. Miranda, J.F. Stevens, T.M. Bray, and E. Ho Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells Cancer Letters 246 2007 201 209
18. S.H. Lee, H.J. Kim, J.S. Lee, I.S. Lee, and B.Y. Kang Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol from hops Archives of Pharmacal Research 30 2007 1435 1439
19. F. Zhao, H. Nozawa, A. Daikonnya, K. Kondo, and S. Kitanaka Inhibitors of nitric oxide production from hops (Humulus lupulus L.) Biological & Pharmaceutical Bulletin 26 2003 61 65
20. R. Dell'Eva, C. Ambrosini, N. Vannini, G. Piaggio, A. Albini, and N. Ferrari AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies Cancer 110 2007 2007 2011
21. S. Monteghirfo, F. Tosetti, C. Ambrosini, S. Stigliani, S. Pozzi, and F. Frassoni Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation Molecular Cancer Therapeutics 7 2008 2692 2702
22. F. Braut-Boucher, J. Pichon, P. Rat, M. Adolphe, M. Aubery, and J. Font A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes Journal of Immunological Methods 178 1995 41 51
23. R. Hussong, N. Frank, J. Knauft, C. Ittrich, R. Owen, and H. Becker A safety study of oral xanthohumol administration and its influence on fertility in Sprague Dawley rats Molecular Nutrition & Food Research 49 2005 861 867
24. B.W. Vanhoecke, F. Delporte, E. Van Braeckel, A. Heyerick, H.T. Depypere, and M. Nuytinck A safety study of oral tangeretin and xanthohumol administration to laboratory mice In Vivo (Athens, Greece) 19 2005 103 107
25. H.E. Skipper, F.M. Schabel Jr., M.W. Trader, and J.R. Thomson Experimental evaluation of potential anticancer agents. VI. Anatomical distribution of leukemic cells and failure of chemotherapy Cancer Research 21 1961 1154 1164
26. C.P. Leith, K.J. Kopecky, I.M. Chen, L. Eijdems, M.L. Slovak, and T.S. McConnell Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study Blood 94 1999 1086 1099
27. C. Saengkhae, C. Loetchutinat, and A. Garnier-Suillerot Kinetic analysis of fluorescein and dihydrofluorescein effluxes in tumor cells expressing the multidrug resistance protein, MRP1 Biochemical Pharmacology 65 2003 969 977
28. S. Shukla, G.T. Maclennan, D.J. Hartman, P. Fu, M.I. Resnick, and S. Gupta Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion International Journal of Cancer 121 2007 1424 1432
29. C.S. Mitsiades, N. Mitsiades, V. Poulaki, R. Schlossman, M. Akiyama, and D. Chauhan Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications Oncogene 21 2002 5673 5683
30. M. Hinz, D. Krappmann, A. Eichten, A. Heder, C. Scheidereit, and M. Strauss NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition Molecular Cell Biology 19 1999 2690 2698
31. C.H. Pui, C. Cheng, W. Leung, S.N. Rai, G.K. Rivera, and J.T. Sandlund Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia The New England Journal of Medicine 349 2003 640 649
32. C.H. Pui Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia Journal of Clinical Oncology 21 2003 179 181
33. S.C. Howard, A.J. Gajjar, C. Cheng, S.B. Kritchevsky, G.W. Somes, and P.L. Harrison Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia JAMA 288 2002 2001 2007
34. O.G. Ottmann, B. Wassmann, H. Pfeifer, A. Giagounidis, M. Stelljes, and U. Duhrsen Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) Cancer 109 2007 2068 2076
35. K. Porkka, P. Koskenvesa, T. Lundan, J. Rimpilainen, S. Mustjoki, and R. Smykla Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood 112 2008 1005 1012
36. M. Stanulla, and M. Schrappe Treatment of childhood acute lymphoblastic leukemia Seminars in Hematology 46 2009 52 63
37. G.J. Kaspers, A.J. Veerman, R. Pieters, C.H. Van Zantwijk, L.A. Smets, and E.R. Van Wering In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia Blood 90 1997 2723 2729
38. D.M. Noonan, R. Benelli, and A. Albini Angiogenesis and cancer prevention: a vision Recent Results in Cancer Research Fortschritte der Krebsforschung 174 2007 219 224
39. A.M. Glodek, Y. Le, D.M. Dykxhoorn, S.Y. Park, G. Mostoslavsky, and R. Mulligan Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-adhesive responses in hematopoietic precursor cells Leukemia 21 2007 1723 1732
40. D.S. Levy, J.A. Kahana, and R. Kumar AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines Blood 113 2009 1723 1729
41. M. Gupta, A.E. Hendrickson, S.S. Yun, J.J. Han, P.A. Schneider, and B.D. Koh Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies Blood 119 2012 476 487
42. L. Wang, J.E. Fortney, and L.F. Gibson Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt Leukemia Research 28 2004 733 742